Gossamer Bio, Inc. Common Stock
Symbol: GOSS (NASDAQ)
2.22
▲ (0.63%) 0.014
Company Description:
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Key Stats
- Today's Open: $2.208
- Today's High: $2.224
- Today's Low: $2.208
- Today's Volume: 0
- Yesterday Close: $2.21
- Yesterday High: $2.22
- Yesterday Low: $2.12
- Yesterday Volume: 2.57M
- Last Min Volume: 0
- Last Min High: $2.224
- Last Min Low: $2.208
- Last Min VWAP: $0
Company Profile
- Name: Gossamer Bio, Inc. Common Stock
- Website: https://www.gossamerbio.com
- Listed Date: 2019-02-08
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001728117
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $498.96M
- Round Lot: 100
- Outstanding Shares: 228.88M
- Asset Type: CS
RECENT FILINGS FOR GOSS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-10-02 | 4 | View |
| 2025-09-25 | 8-K | View |
| 2025-08-20 | 4 | View |
| 2025-08-05 | 8-K | View |
| 2025-08-05 | 10-Q | View |
| 2025-07-29 | SCHEDULE 13G | View |
| 2025-07-17 | SCHEDULE 13G | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-25 | 8-K | View |
| 2025-06-16 | 8-K | View |
Latest News on GOSS